ArticleInternational journal of clinical oncology2014
Clinical utility and limitations of FDG PET in detecting recurrent hepatocellular carcinoma in postoperative patients.
Article in International journal of clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- 18F-FDG PET with or without CT in the diagnosis of extrahepatic metastases or local residual/recurrent hepatocellular carcinoma.Medicine · 2018Pooled it
- Diagnostic performance of [European journal of nuclear medicine and molecular imaging · 2025Trial
- Exploring the efficacy ofAbdominal radiology (New York) · 2023Article
- Different Features ofCancer management and research · 2022Article
- Clinical management and susceptibility of primary hepatic lymphoma: A cases-based retrospective study.World journal of clinical cases · 2021Article
- Article
- Prognostic Value of Metabolic Imaging Data ofCancers · 2021Article
- Biological Evaluation of [Frontiers in chemistry · 2021Article
- Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects.World journal of gastroenterology · 2019Review
- Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.European journal of nuclear medicine and molecular imaging · 2017Article
- Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects.World journal of gastroenterology · 2016Review
- A non-smooth tumor margin on preoperative imaging predicts microvascular invasion of hepatocellular carcinoma.Surgery today · 2016Article
- [Research progress in metabolic and receptor-like nuclear imaging agents for hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2016Article
- Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.World journal of gastroenterology · 2015Review
- Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication.World journal of biological chemistry · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical usefulness of positron emission tomography (PET) with (18)F-fluorodeoxyglucose (FDG) for the detection of recurrent hepatocellular carcinoma (HCC) is controversial because HCC displays varying FDG avidity. The purposes of this study were to re-evaluate the utility of FDG PET for the detection of recurrent HCC, and to assess its prognostic value in a large series of postoperative patients.
methodsWe retrospectively reviewed 113 scans in 86 patients undergoing FDG PET after curative surgery for HCC. These scans were performed for suspected recurrence on radiologic imaging (group A: n = 44) because of an elevated tumor marker level with negative prior imaging results (group B: n = 32) or with no suspicion of recurrence (group C: n = 37). FDG PET's accuracy for recurrence detection and its value as a predictor of survival were assessed.
resultsThe sensitivity, specificity, and diagnostic accuracy were 53, 100, and 55 % for group A; 34, 100, and 41 % for group B; and 11, 100, and 78 % for group C, respectively. A change in therapy resulted from the scan results in 7, 9, and 8 % in groups A, B, and C, respectively. The combined sensitivities for intra- and extrahepatic recurrence were 30 and 42 %, respectively. Histopathological features at initial surgery did not affect the sensitivity. The overall survival of patients with positive scans was significantly poorer than that of patients with negative scans (P = 0.008).
conclusionsThe sensitivity of FDG PET for recurrent HCC was low, with little change in treatment resulting. However, it can predict prognosis in postoperative patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.